Mannkind Corporation
MNKDMannkind Corporation is a biotechnology company focused on discovering, developing, and commercializing inhaled therapeutic products. It is best known for its flagship product, Afrezza, an inhalable insulin used to improve blood sugar control in people with diabetes. The company also develops other inhaled and injectable drug delivery systems aimed at providing innovative solutions for various medical conditions.
Company News
MannKind announced new clinical and real-world data for Afrezza (inhaled insulin) presented at the ADA 2026 Scientific Sessions, following the FDA approval for pediatric use (ages 6+) in May 2026. Key findings include greater treatment satisfaction in pediatric patients, comparable efficacy to rapid-acting analogs, potential use with automated in...
MannKind Corporation announced FDA approval of Afrezza®, the first and only inhaled mealtime insulin for children and adolescents aged 6 and older with diabetes. The company will host a conference call on May 29, 2026 at 4:30 p.m. Eastern with CEO Michael Castagna and other executives to discuss the approval.
MannKind Corporation reported Q1 2026 total revenues of $90.2M, representing 15% growth compared to Q1 2025. The company announced CEO Michael Castagna will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3. MannKind also plans to showcase new data on inhaled insulin (Afrezza®) in pediatric care, pregnan...
The point-of-care diagnostics market has reached $58.76 billion globally in 2026, growing at nearly 10% annually, with projections to reach $114.65 billion by 2035. Five companies are leading this structural shift toward decentralized, consumer-facing healthcare: VentriPoint Diagnostics is expanding globally with AI-powered cardiac imaging; Hims ...
Avaà Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in...
